Bristol-Myers: positive results for Opdivo with Cabometyx
(CercleFinance.com) - Ipsen announces the first presentation of positive results from the pivotal Phase III CheckMate 9ER study of its Cabometyx (cabozantinib), in association with Bristol Myers Squibb's Opdivo, in previously untreated advanced kidney carcinoma.
It points out that this combination demonstrated superior overall survival and doubled median progression-free survival and the objective response rate compared to sunitinib, with a favourable safety profile.
Patients treated with Cabometyx in combination with Opdivo reported significantly better health-related quality of life than those treated with sunitinib in most evaluations, the group said.
Copyright (c) 2020 CercleFinance.com. All rights reserved.